Xu Rui, Wang Sheng-Yu, Wang Li, Li Man-Xiang, Yao Yang
1Department of Respiratory Medicine, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; 2Department of Respiratory Medicine, First Affiliated Hospital of Xi'an Medical University, Xi'an 710061, China. E-mail:
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Mar 20;38(3):329-333. doi: 10.3969/j.issn.1673-4254.2018.03.14.
To investigate the expression of CHCHD2, a potential tumor marker, in tumor and adjacent tissues from patients with non-small cell lung cancer (NSCLC).
Immunohistochemistry was used to detect the expression and location of CHCHD2 in the tumor tissues from 60 patients with NSCLC and 35 adjacent tissues to analyze the correlation of CHCHD2 expression with the clinicopathological variables and overall survival of the patients. The expression profile of CHCHD2 mRNA in NSCLC was analyzed using Oncomine database.
The positivity rate of CHCHD2 was significantly higher in the tumor tissues than in adjacent tissues in patients with NSCLC (75.0% vs 17.1%). CHCHD2 positivity in the tumor tissues was associated with lymph node metastasis, pathological TNM stage, and tumor grades but not with age, gender, or histological type of the tumors. Analysis using Oncomine database showed that CHCHD2 mRNA was expressed at significantly higher levels in NSCLC than in normal control group (P<0.05). Kaplan-Meier survival analysis showed that NSCLC patients with a positive expression of CHCHD2 had a significantly shorter overall survival time than those negative for CHCHD2 (P<0.05).
As a potential tumor marker, CHCHD2 over-expression plays a role in the occurrence and progression of NSCLC and promotes tumor invasion and metastasis, and can potentially serve as an indicator for early diagnosis and prognostic evaluation of NSCLC.
研究潜在肿瘤标志物CHCHD2在非小细胞肺癌(NSCLC)患者肿瘤组织及癌旁组织中的表达情况。
采用免疫组织化学法检测60例NSCLC患者肿瘤组织及35例癌旁组织中CHCHD2的表达及定位,分析CHCHD2表达与患者临床病理变量及总生存期的相关性。利用Oncomine数据库分析NSCLC中CHCHD2 mRNA的表达谱。
NSCLC患者肿瘤组织中CHCHD2的阳性率显著高于癌旁组织(75.0% 对17.1%)。肿瘤组织中CHCHD2阳性与淋巴结转移、病理TNM分期及肿瘤分级相关,但与患者年龄、性别或肿瘤组织学类型无关。Oncomine数据库分析显示,NSCLC中CHCHD2 mRNA表达水平显著高于正常对照组(P<0.05)。Kaplan-Meier生存分析显示,CHCHD2表达阳性的NSCLC患者总生存时间显著短于CHCHD2阴性患者(P<0.05)。
作为一种潜在的肿瘤标志物,CHCHD2过表达在NSCLC的发生发展中起作用,促进肿瘤侵袭和转移,并有可能作为NSCLC早期诊断和预后评估的指标。